Single User License
INR 136040
Site License
INR 272080
Corporate User License
INR 408120

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Chronic Heart Failure-Pipeline Review, H1 2015

Chronic Heart Failure-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Chronic Heart Failure-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Chronic Heart Failure-Pipeline Review, H1 2015', provides an overview of the Chronic Heart Failure's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Chronic Heart Failure, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Heart Failure and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Chronic Heart Failure

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Chronic Heart Failure and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Chronic Heart Failure products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Chronic Heart Failure pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Chronic Heart Failure

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Chronic Heart Failure pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Chronic Heart Failure Overview 9

Therapeutics Development 10

Pipeline Products for Chronic Heart Failure-Overview 10

Pipeline Products for Chronic Heart Failure-Comparative Analysis 11

Chronic Heart Failure-Therapeutics under Development by Companies 12

Chronic Heart Failure-Therapeutics under Investigation by Universities/Institutes 13

Chronic Heart Failure-Pipeline Products Glance 14

Late Stage Products 14

Clinical Stage Products 15

Early Stage Products 16

Chronic Heart Failure-Products under Development by Companies 17

Chronic Heart Failure-Products under Investigation by Universities/Institutes 19

Chronic Heart Failure-Companies Involved in Therapeutics Development 20

Amgen Inc. 20

AnGes MG, Inc. 21

ARCA biopharma, Inc. 22

Bayer AG 23

Bial-Portela & Ca, S.A. 24

Celyad 25

Jiangsu Hengrui Medicine Co., Ltd. 26

Laboratoires Pierre Fabre SA 27

Les Laboratoires Servier SAS 28

Mesoblast Limited 29

Novartis AG 30

Pfizer Inc. 31

PhaseBio Pharmaceuticals, Inc. 32

Sanofi 33

Stemedica Cell Technologies, Inc. 34

Zensun (Shanghai) Sci & Tech Co., Ltd. 35

Chronic Heart Failure-Therapeutics Assessment 36

Assessment by Monotherapy Products 36

Assessment by Combination Products 37

Assessment by Target 38

Assessment by Mechanism of Action 40

Assessment by Route of Administration 42

Assessment by Molecule Type 44

Drug Profiles 46

(sacubitril + valsartan)-Drug Profile 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

aliskiren fumarate-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

BAY-1067197-Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

beperminogene perplasmid-Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

BIA-51058-Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

BR-5489-Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

C3BSCQR-1-Drug Profile 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

carvedilol phosphate ER-Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

cenderitide-Drug Profile 62

Product Description 62

Mechanism of Action 62

R&D Progress 62

F-373280-Drug Profile 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

finerenone-Drug Profile 65

Product Description 65

Mechanism of Action 65

R&D Progress 65

furosemide-Drug Profile 66

Product Description 66

Mechanism of Action 66

R&D Progress 66

ivabradine-Drug Profile 67

Product Description 67

Mechanism of Action 67

R&D Progress 67

Mesenchymal Stem Cells-Drug Profile 68

Product Description 68

Mechanism of Action 68

R&D Progress 68

MPC-150IM-Drug Profile 70

Product Description 70

Mechanism of Action 70

R&D Progress 70

Neucardin-Drug Profile 72

Product Description 72

Mechanism of Action 72

R&D Progress 72

omecamtiv mecarbil-Drug Profile 75

Product Description 75

Mechanism of Action 75

R&D Progress 75

PB-1046-Drug Profile 78

Product Description 78

Mechanism of Action 78

R&D Progress 78

Peptide to Activate Erythropoietin Receptor for Cardiovascular Diseases-Drug Profile 80

Product Description 80

Mechanism of Action 80

R&D Progress 80

rivaroxaban-Drug Profile 81

Product Description 81

Mechanism of Action 81

R&D Progress 81

RNAi Gene Therapy to Inhibit STIM1 for Chronic Heart Failure and Atherosclerosis-Drug Profile 86

Product Description 86

Mechanism of Action 86

R&D Progress 86

SAR-296968-Drug Profile 87

Product Description 87

Mechanism of Action 87

R&D Progress 87

serelaxin-Drug Profile 88

Product Description 88

Mechanism of Action 88

R&D Progress 88

sildenafil citrate-Drug Profile 91

Product Description 91

Mechanism of Action 91

R&D Progress 91

Small Molecule to Inhibit Beta-1 Adrenergic Receptor for Chronic Heart Failure-Drug Profile 93

Product Description 93

Mechanism of Action 93

R&D Progress 93

vericiguat-Drug Profile 94

Product Description 94

Mechanism of Action 94

R&D Progress 94

Chronic Heart Failure-Recent Pipeline Updates 95

Chronic Heart Failure-Dormant Projects 130

Chronic Heart Failure-Product Development Milestones 132

Featured News & Press Releases 132

Apr 15, 2015: FDA Approves Corlanor (ivabradine) To Reduce The Risk Of Hospitalization For Worsening Heart Failure In Patients With Chronic Heart Failure 132

Mar 10, 2015: CardioCell Adds Stony Brook University to Sites Conducting a Phase IIa Clinical Trial Using Its Stem Cells for Patients With Chronic Heart Failure 133

Mar 09, 2015: An International Multi-center Phase III Clinical Trial of Recombinant Human Neuregulin-1 is going to Launch 134

Mar 02, 2015: Cardio3 BioSciences marks first important milestone in regulatory path toward C-Cure market registration with Paediatric Investigation Plan waiver from EMA 134

Mar 02, 2015: Amgen Showcases Cardiovascular Pipeline At ACC.15 With Chronic Heart Failure Data 134

Feb 13, 2015: Novartis heart failure medicine LCZ696 granted FDA priority review 136

Nov 20, 2014: University of Pennsylvania Doses First Patient in Phase IIa Clinical Trial Using CardioCell's Stem Cell Therapy to Treat Chronic Heart Failure Due to Non-Ischemic Cardiomyopathy 136

Sep 14, 2014: Amgen Presents Analyses Of Phase 3 Ivabradine Data For The Treatment Of Chronic Heart Failure 137

Aug 27, 2014: FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure 138

Jul 08, 2014: CardioCell Begins Phase IIa Clinical Trial Using itMSC Therapy to Treat Chronic Heart Failure (HF) Due to Non-Ischemic Cardiomyopathy 139

Appendix 141

Methodology 141

Coverage 141

Secondary Research 141

Primary Research 141

Expert Panel Validation 141

Contact Us 141

Disclaimer 142

List of Tables

Number of Products under Development for Chronic Heart Failure, H1 2015 10

Number of Products under Development for Chronic Heart Failure-Comparative Analysis, H1 2015 11

Number of Products under Development by Companies, H1 2015 12

Number of Products under Investigation by Universities/Institutes, H1 2015 13

Comparative Analysis by Late Stage Development, H1 2015 14

Comparative Analysis by Clinical Stage Development, H1 2015 15

Comparative Analysis by Early Stage Development, H1 2015 16

Products under Development by Companies, H1 2015 17

Products under Development by Companies, H1 2015 (Contd..1) 18

Products under Investigation by Universities/Institutes, H1 2015 19

Chronic Heart Failure-Pipeline by Amgen Inc., H1 2015 20

Chronic Heart Failure-Pipeline by AnGes MG, Inc., H1 2015 21

Chronic Heart Failure-Pipeline by ARCA biopharma, Inc., H1 2015 22

Chronic Heart Failure-Pipeline by Bayer AG, H1 2015 23

Chronic Heart Failure-Pipeline by Bial-Portela & Ca, S.A., H1 2015 24

Chronic Heart Failure-Pipeline by Celyad, H1 2015 25

Chronic Heart Failure-Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H1 2015 26

Chronic Heart Failure-Pipeline by Laboratoires Pierre Fabre SA, H1 2015 27

Chronic Heart Failure-Pipeline by Les Laboratoires Servier SAS, H1 2015 28

Chronic Heart Failure-Pipeline by Mesoblast Limited, H1 2015 29

Chronic Heart Failure-Pipeline by Novartis AG, H1 2015 30

Chronic Heart Failure-Pipeline by Pfizer Inc., H1 2015 31

Chronic Heart Failure-Pipeline by PhaseBio Pharmaceuticals, Inc., H1 2015 32

Chronic Heart Failure-Pipeline by Sanofi, H1 2015 33

Chronic Heart Failure-Pipeline by Stemedica Cell Technologies, Inc., H1 2015 34

Chronic Heart Failure-Pipeline by Zensun (Shanghai) Sci & Tech Co., Ltd., H1 2015 35

Assessment by Monotherapy Products, H1 2015 36

Assessment by Combination Products, H1 2015 37

Number of Products by Stage and Target, H1 2015 39

Number of Products by Stage and Mechanism of Action, H1 2015 41

Number of Products by Stage and Route of Administration, H1 2015 43

Number of Products by Stage and Molecule Type, H1 2015 45

Chronic Heart Failure Therapeutics-Recent Pipeline Updates, H1 2015 95

Chronic Heart Failure-Dormant Projects, H1 2015 130

Chronic Heart Failure-Dormant Projects (Contd..1), H1 2015 131

List of Figures

Number of Products under Development for Chronic Heart Failure, H1 2015 10

Number of Products under Development for Chronic Heart Failure-Comparative Analysis, H1 2015 11

Number of Products under Development by Companies, H1 2015 12

Comparative Analysis by Late Stage Development, H1 2015 14

Comparative Analysis by Clinical Stage Development, H1 2015 15

Comparative Analysis by Early Stage Products, H1 2015 16

Assessment by Monotherapy Products, H1 2015 36

Number of Products by Top 10 Targets, H1 2015 38

Number of Products by Stage and Top 10 Targets, H1 2015 38

Number of Products by Top 10 Mechanism of Actions, H1 2015 40

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 40

Number of Products by Top 10 Routes of Administration, H1 2015 42

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 43

Number of Products by Top 10 Molecule Types, H1 2015 44

Number of Products by Stage and Top 10 Molecule Types, H1 2015 45

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Amgen Inc.

AnGes MG, Inc.

ARCA biopharma, Inc.

Bayer AG

Bial - Portela & Ca, S.A.

Celyad

Jiangsu Hengrui Medicine Co., Ltd.

Laboratoires Pierre Fabre SA

Les Laboratoires Servier SAS

Mesoblast Limited

Novartis AG

Pfizer Inc.

PhaseBio Pharmaceuticals, Inc.

Sanofi

Stemedica Cell Technologies, Inc.

Zensun (Shanghai) Sci & Tech Co., Ltd.

Chronic Heart Failure Therapeutic Products under Development, Key Players in Chronic Heart Failure Therapeutics, Chronic Heart Failure Pipeline Overview, Chronic Heart Failure Pipeline, Chronic Heart Failure Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com